aamdsbook_coverNew Multi-Touch iBook® Textbook Now Available for free from the Apple® iBookstore

Carden Jennings Publishing Co., Ltd., a leader in multimedia medical education and publishing, is pleased to announce release of another title in the series of its CJP Interactive Updates™, Grand Rounds in Hematology: Interactive Updates in Myelodysplastic Syndromes

Aplastic anemia (AA), the myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are rare diseases that all result in bone marrow failure—the ineffective formation of circulating blood cells—leading to anemia, bleeding, infection, and death in many cases, even with modern therapies. Once thought of as distinct, these three diseases are now believed to be linked by similar pathophysiologic pathways. Of the three bone marrow failure diseases, MDS currently has the largest number of therapeutic drugs available, although none of them is curative. Much of the current confusion and controversy in MDS treatment stems from the lack of consensus on which therapies to use in which patients, and what realistic outcomes might be.
Currently there are limited options for MDS patients that are failing hypomethylating therapy. Work is still to be done on optimizing the delivery of hypomethylating therapies by dosing appropriately, sequencing appropriately, and using thoughtful combinations. There is also a need to improve drug formulations, whether it is an oral formulation or a novel formulation, in selecting patients for directed therapy. Hopefully with improvement of a better understanding of the mechanisms of resistance, or even mechanisms of actions with available agents, drug targeting in patients with MDS will improve.

Grand Rounds in Hematology: Interactive Updates in Myelodysplastic Syndromes includes expert contributions and imagery on the following topics:

    Lecture on MDS vs. AML: How Different?

Elihu H. Estey, MD

    Biology and Clinics of Resistance/ Failure to Hypomethylating Agents

Hetty Carraway, MD, MBA

    Lecture on Potential Sources for Clinical Heterogeneity in del5q Myelodysplastic Syndromes (MDS)

David P. Steensma, MD, FACP

    The Challenge of Prognosis and Sequential Therapy in Lower-Risk MDS

Valeria Santini, MD

For CME questions, please E-mail: info@mer.org. If you wish to receive acknowledgment of participation for this activity, please complete the post-test by selecting the best answer to each question. Complete this test and mail to Medical Education Resources, 9785 South Maroon Circle, Suite 100, Englewood, CO 80112; or fax to 303-798-5731. Click here for CME Post-Test.

Download on the Apple® iBookstore